The study investigates cGAS–STING pathway activation in tumors. In genO-BRGSF-HIS mice, STING activation reprogrammed human myeloid cells to promote pro-inflammatory cytokine production, dendritic cell maturation, and T cell-mediated tumor killing.
STING agonist treatment triggered strong human innate responses, boosted T cell infiltration, and improved tumor control in humanized mice.
genO-BRGSF-HIS humanized mouse — genOway-developed, CD34+ HSC-engrafted
Tumor microenvironment, innate immunity, STING activation, humanized mouse models, T cell reprogramming
CD34+ HSC engraftment in BRGSF mice, STING agonist treatment, tumor challenge, immune profiling via flow cytometry, cytokine quantification
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
